Tweet
Genetic Engineering News (press release), NY
Breaking News
ImaRx Therapeutics Names Richard L. Love as Chairman
and Announces Management Appointments
Sep 20 2007, 7:00 AM EST
News source: Business Wire
ImaRx Therapeutics, Inc. (NASDAQ:IMRX) today announced it has named
Richard L. Love as Chairman of the Board of Directors. He succeeds
Richard E. Otto, who will remain on the company's board. Mr. Love has
served on the ImaRx board since March 2006. Previously, he served as
Chief Operating Officer for Translational Genomics Research Institute
and from June 1993 to January 2002 served as Chief Executive Officer
and a director of ILEX Oncology, Inc., a biotechnology company
evaluating cancer therapeutics. Mr. Love holds bachelors and masters
of science degrees in Chemical Engineering from the Virginia
Polytechnic Institute.
"Richard Otto has provided sound leadership and guidance to the
company in supporting the advancement of its technology for the
treatment of stroke. Richard also played a key role in directing
ImaRx's recent transition from a private to a publicly traded
company. I look forward to continuing to work with Richard as well as
Brad Zakes and the ImaRx management team to advance the company's
programs, develop business opportunities, and create value for our
shareholders," said Mr. Love.
The company also announced that it has named Garen Manvelian, M.D., as
Chief Medical Officer and that Jennifer Marshall was promoted to Vice
President, Corporate Development. Dr. Manvelian will direct the
company's ongoing Sonolysis(TM) microbubble clinical program, as well
as oversee medical affairs of the company's commercial product,
Abbokinase(R). He will report to Bradford Zakes, ImaRx' President and
Chief Executive Officer.
Prior to joining ImaRx, Dr. Manvelian was Chief Medical Officer, Vice
President of Clinical and Regulatory Affairs for New River
Pharmaceuticals. Previous to that, he was Senior Director, Clinical
and Medical Affairs, for SkyePharma, Inc. Dr. Manvelian holds an
M.D. degree from the Vitebsk State Medical Institute in Vitebsk,
Belarus. He completed a residency program in anesthesiology at the
Republic Hospital of Armenia in Yerevan, Armenia, and a postdoctoral
fellowship at the Yale University School of Medicine Department of
Anesthesiology.
"We are very excited to have Dr. Manvelian join our management
team. His knowledge and experience will be an important factor in
advancing our products through clinical trials," said
Mr. Zakes. Dr. Manvelian commented, "I look forward to working with
the ImaRx team. I am enthusiastic to begin working in this exciting
field of therapy. This opportunity will allow me to apply my
experience to help advance the company's compounds toward regulatory
approval."
Ms. Marshall, a seven-year veteran of ImaRx, will be responsible for
overseeing and guiding the strategic direction for corporate
development activities within ImaRx. She will also be managing the
company's investor relations activities. Previously, Ms. Marshall was
the company's Senior Director, Finance and Corporate Development.
"We are very pleased to recognize the contribution of Jennifer
Marshall to our recent progress. This well-deserved promotion reflects
her drive and dedication to ImaRx," said Mr. Zakes.
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and
commercializing therapies for vascular disorders. The company's
research and development efforts are focused on therapies for stroke
and other vascular disorders using its proprietary microbubble
technology. ImaRx Therapeutics' commercialization efforts are
currently focused on its product, Abbokinase(R), for the treatment of
acute massive pulmonary embolism.
Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions
Of The Private Securities Litigation Reform Act of 1995
Note: Statements made in this press release which are not historical
in nature constitute forward-looking statements for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current
expectations and beliefs and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. A more
complete description of these risks can be found in the company's
filings with the Securities and Exchange Commission.
Breaking News
ImaRx Therapeutics Names Richard L. Love as Chairman
and Announces Management Appointments
Sep 20 2007, 7:00 AM EST
News source: Business Wire
ImaRx Therapeutics, Inc. (NASDAQ:IMRX) today announced it has named
Richard L. Love as Chairman of the Board of Directors. He succeeds
Richard E. Otto, who will remain on the company's board. Mr. Love has
served on the ImaRx board since March 2006. Previously, he served as
Chief Operating Officer for Translational Genomics Research Institute
and from June 1993 to January 2002 served as Chief Executive Officer
and a director of ILEX Oncology, Inc., a biotechnology company
evaluating cancer therapeutics. Mr. Love holds bachelors and masters
of science degrees in Chemical Engineering from the Virginia
Polytechnic Institute.
"Richard Otto has provided sound leadership and guidance to the
company in supporting the advancement of its technology for the
treatment of stroke. Richard also played a key role in directing
ImaRx's recent transition from a private to a publicly traded
company. I look forward to continuing to work with Richard as well as
Brad Zakes and the ImaRx management team to advance the company's
programs, develop business opportunities, and create value for our
shareholders," said Mr. Love.
The company also announced that it has named Garen Manvelian, M.D., as
Chief Medical Officer and that Jennifer Marshall was promoted to Vice
President, Corporate Development. Dr. Manvelian will direct the
company's ongoing Sonolysis(TM) microbubble clinical program, as well
as oversee medical affairs of the company's commercial product,
Abbokinase(R). He will report to Bradford Zakes, ImaRx' President and
Chief Executive Officer.
Prior to joining ImaRx, Dr. Manvelian was Chief Medical Officer, Vice
President of Clinical and Regulatory Affairs for New River
Pharmaceuticals. Previous to that, he was Senior Director, Clinical
and Medical Affairs, for SkyePharma, Inc. Dr. Manvelian holds an
M.D. degree from the Vitebsk State Medical Institute in Vitebsk,
Belarus. He completed a residency program in anesthesiology at the
Republic Hospital of Armenia in Yerevan, Armenia, and a postdoctoral
fellowship at the Yale University School of Medicine Department of
Anesthesiology.
"We are very excited to have Dr. Manvelian join our management
team. His knowledge and experience will be an important factor in
advancing our products through clinical trials," said
Mr. Zakes. Dr. Manvelian commented, "I look forward to working with
the ImaRx team. I am enthusiastic to begin working in this exciting
field of therapy. This opportunity will allow me to apply my
experience to help advance the company's compounds toward regulatory
approval."
Ms. Marshall, a seven-year veteran of ImaRx, will be responsible for
overseeing and guiding the strategic direction for corporate
development activities within ImaRx. She will also be managing the
company's investor relations activities. Previously, Ms. Marshall was
the company's Senior Director, Finance and Corporate Development.
"We are very pleased to recognize the contribution of Jennifer
Marshall to our recent progress. This well-deserved promotion reflects
her drive and dedication to ImaRx," said Mr. Zakes.
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and
commercializing therapies for vascular disorders. The company's
research and development efforts are focused on therapies for stroke
and other vascular disorders using its proprietary microbubble
technology. ImaRx Therapeutics' commercialization efforts are
currently focused on its product, Abbokinase(R), for the treatment of
acute massive pulmonary embolism.
Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions
Of The Private Securities Litigation Reform Act of 1995
Note: Statements made in this press release which are not historical
in nature constitute forward-looking statements for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current
expectations and beliefs and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. A more
complete description of these risks can be found in the company's
filings with the Securities and Exchange Commission.